Münzel等回复关于尼古丁替代疗法(NRT)与尼古丁消费品的区分
Reply to ‘Distinguishing between nicotine replacement therapies and nicotine-containing consumer products’
Münzel等回复Berlin和Thomas的来信,确认尼古丁替代疗法(NRT)是独立于其他尼古丁消费品的严评药品,但认为短期临床试验证据未解决NRT心血管安全性问题。作者强调尼古丁包括NRT在内的对心血管的影响并非生物学惰性,并欢迎澄清立场。
- Correspondence
- Published: 22 October 2026
- Thomas Münzel ORCID: orcid.org/0000-0001-5503-41501,2,
- Marin Kuntic1,2,
- John F. Keaney3,
- Julia Lurz1,
- Filippo Crea4,
- Thomas F. Lüscher ORCID: orcid.org/0000-0002-5259-538X5,6,7,8,
- Sanjay Rajagopalan9 &
- …
- Andreas Daiber ORCID: orcid.org/0000-0002-2769-00941,2
Nature Reviews Cardiology (2026) Cite this article
We thank Berlin and Thomas for their Correspondence on our Review (Münzel, T. et al. Nicotine-containing products and the cardiovascular system: mechanisms and global health implications. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-026-01331-6; 2026)1 and for the issues raised (Berlin, I. & Thomas, D. Distinguishing between nicotine replacement therapies and nicotine-containing consumer products. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-026-01362-z; 2026)2; we welcome the opportunity to clarify our position on nicotine replacement therapy (NRT). We agree that NRT occupies a distinct regulatory and clinical category from that of other nicotine-containing consumer products: NRT is a rigorously evaluated, quality-controlled medication with a well-established net benefit for smoking cessation, and nothing in our Review was intended to discourage its prescription.
However, we do not agree that the evidence from short-term clinical trials cited by Berlin and Thomas settles the question of the cardiovascular safety of NRT, and we think that their Correspondence illustrates precisely the point that we raised in our Review — that the cardiovascular effects of nicotine, including from NRT, should not be regarded as biologically inert.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
27.99 € / 30 days cancel any time
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
References
Münzel, T. et al. Nicotine-containing products and the cardiovascular system: mechanisms and global health implications. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-026-01331-6 (2026).
Berlin, I. & Thomas, D. Distinguishing between nicotine replacement therapies and nicotine-containing consumer products. Nat. Rev. Cardiol. https://doi.org/10.1038/s41569-026-01362-z (2026).
Mills, E. J., Thorlund, K., Eapen, S., Wu, P. & Prochaska, J. J. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 129, 28–41 (2014).
Hartmann-Boyce, J., Chepkin, S. C., Ye, W., Bullen, C. & Lancaster, T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst. Rev. 5, CD000146 (2018).
Dollerup, J. et al. Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. Clin. Epidemiol. 9, 231–243 (2017).
Mills, E. J., Wu, P., Lockhart, I., Wilson, K. & Ebbert, J. O. Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob. Induc. Dis. 8, 8 (2010).
Münzel, T., Crea, F., Rajagopalan, S. & Lüscher, T. F. Nicotine and the cardiovascular system: unmasking a global public health threat. Eur. Heart J. 47, 1764–1781 (2026).
Author information
Authors and Affiliations
University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany
Thomas Münzel, Marin Kuntic, Julia Lurz & Andreas Daiber
German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany
Thomas Münzel, Marin Kuntic & Andreas Daiber
Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA, USA
John F. Keaney
Center of Excellence of Cardiovascular Sciences, Ospedale Isola Tiberina – Gemelli Isola, Rome, Italy
Filippo Crea
Heart Division, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
Thomas F. Lüscher
School of Cardiovascular and Metabolic Medicine and Sciences, King’s College London, London, UK
Thomas F. Lüscher
National Heart and Lung Institute, Imperial College, London, UK
Thomas F. Lüscher
Center for Molecular Cardiology, University of Zurich, Schlieren-Zurich, Switzerland
Thomas F. Lüscher
University Hospitals, Harrington Heart and Vascular Institute, Case Western Reserve School of Medicine, Cleveland, OH, USA
Sanjay Rajagopalan
Authors
- Thomas Münzel
- Marin Kuntic
- John F. Keaney
- Julia Lurz
- Filippo Crea
- Thomas F. Lüscher
- Sanjay Rajagopalan
- Andreas Daiber
Corresponding author
Correspondence to Thomas Münzel.
Ethics declarations
Competing interests
The authors declare no competing interests.
About this article
Cite this article
Münzel, T., Kuntic, M., Keaney, J.F. et al. Reply to ‘Distinguishing between nicotine replacement therapies and nicotine-containing consumer products’. Nat Rev Cardiol (2026). https://doi.org/10.1038/s41569-026-01361-0
Published: 22 October 2026
Version of record: 22 October 2026
DOI: https://doi.org/10.1038/s41569-026-01361-0
来源:Nature 健康护理主题 · nature.com